GWAS and HLA subtyping in autoimmune encephalitis

GWAS and HLA subtyping in autoimmune encephalitis - GWAS and HLA in autoimmune encephalitis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON49804

Enrollment

300

Registered

2020-11-10

Start date

2020-11-19

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

autoimmune encephalitis Brain inflammation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age of 18 years and older. - Diagnosis of autoimmune encephalitis (neuronal antibodies proven in serum or CSF).

Exclusion criteria

Exclusion criteria: - Patient and/or legal representative is withholding informed consent. - Patient objects after initial informed consent.

Design outcomes

Primary

Measure	Time frame
1. Identification of a HLA allele or allelic combination associated in patients with autoimmune encephalitis. 2. Determination of genetic risk factors for the development of autoimmune encephalitis using Genome-Wide Association Studies (GWAS).	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results